Literature DB >> 14757506

A common pathway of nitric oxide release from AZD3582 and glyceryl trinitrate.

Georg Berndt1, Nina Grosser, Janet Hoogstraate, Henning Schröder.   

Abstract

4-(Nitrooxy)-butyl-(S)-2-(6-methoxy-2-naphthyl)-propanoate (AZD3582) is a cyclooxygenase (COX)-inhibiting nitric oxide donator (CINOD). It donates nitric oxide (NO) in biological systems through as yet unidentified mechanisms. cGMP, a marker of intracellularly generated NO, was increased up to 27-fold over basal levels by AZD3582 (1-30microM) in LLC-PK1 kidney epithelial cells. A 5h pretreatment with glyceryl tinitrate (GTN, 0.1-1microM) attenuated the cGMP response to a subsequent challenge with AZD3582 or GTN. Similarly, AZD3582 (10-30microM) pretreatment reduced the increase in cGMP on subsequent incubation with AZD3582 or GTN. In contrast, cGMP stimulation by SIN-1, which releases NO independently of enzymatic catalysis, remained unimpaired in cells pretreated with GTN or AZD3582. Our results demonstrate that AZD3582 decreases the sensitivity of the guanylyl cyclase/cGMP system to GTN and vice versa. This suggests that bioactivation pathways for organic nitrates, which involve enzymatic catalysis, may be responsible for NO donation from AZD3582.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14757506     DOI: 10.1016/j.ejps.2003.10.020

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  5 in total

1.  Treatment strategies for osteoarthritis patients with pain and hypertension.

Authors:  Paolo Verdecchia; Fabio Angeli; Giovanni Mazzotta; Paola Martire; Marta Garofoli; Giorgio Gentile; Gianpaolo Reboldi
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-08       Impact factor: 5.346

2.  Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo.

Authors:  L Christofer Adding; Per Agvald; Lars I Andersson; Bror Jonzon; Janet Hoogstraate; Lars E Gustafsson
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

Review 3.  Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs.

Authors:  Matthias Hermann
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

4.  A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.

Authors:  L S Lohmander; D McKeith; O Svensson; M Malmenäs; L Bolin; A Kalla; G Genti; J Szechinski; C Ramos-Remus
Journal:  Ann Rheum Dis       Date:  2004-09-02       Impact factor: 19.103

Review 5.  Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritis.

Authors:  Isla S Mackenzie; Daniel Rutherford; Thomas M MacDonald
Journal:  Arthritis Res Ther       Date:  2008-10-17       Impact factor: 5.156

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.